Please login to the form below

Not currently logged in
Email:
Password:

Boehringer builds evidence base for its Humira biosimilar

Cyltezo shows clinical equivalence to AbbVie's blockbuster in a late-stage trial

BI

Boehringer Ingelheim has released positive phase III data for Cyltezo (adalimumab-adbm), its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.

The one-year VOLTAIRE-RA study of 645 adults with moderately-to-severely active rheumatoid arthritis, showed Cyltezo is equivalent, with no clinically meaningful difference in efficacy, safety and immunogenicity, to Humira.

Karsten Kissel, head of global medical affairs biosimilars, Boehringer Ingelheim, said: “These data are an important addition to the robust body of evidence demonstrating Cyltezo is biosimilar to Humira.

“Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with inflammatory disease like RA.”

Though not on the European market just yet, Cyltezo is set to gain a licence within the coming months after receiving a position opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP). That recommendation covered its use to treat adults with multiple chronic inflammatory diseases, including moderate to severe active rheumatoid arthritis, psoriatic arthritis and moderate to severely active Crohn’s disease.

The CHMP also recommended Cyltezo for paediatric patients, in indications such as moderate to severe Crohn’s disease, severe chronic plaque psoriasis, enthesitis-releated arthritis, and polyarticular juvenile idiopathic arthritis.

Usually, a CHMP opinion would be a big confidence boost to a pharma firm looking to market its product in the EU, however Boehringer and AbbVie are currently locked in US patent litigation trial in the US, ensuring Boehringer treads carefully in Europe.

Consequently, Boehringer has said that it “does not intend to launch Cyltezo in the EU before expiration of the respective SPC for adalimumab in October 2018”.

In the US AbbVie wants to keep Cyltezo off the market, claiming it will infringe 74 of its patents. However, Boehringer will still push on with presenting its new data at the forthcoming Association of Rheumatology Health Professionals annual meeting in California, US.

Meanwhile, in a similar suit, AbbVie has successfully blocked US marketing of Amgen’s biosimilar version of Humira up until 2023, although in this case AbbVie only claimed Amgen was infringing on ten of its patent rights.

Article by
Gemma Jones

8th November 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...
arrow
Patently unclear?
The challenge of protecting biotech innovations...

Infographics